Ira M. Longini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ira M. Longini has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Claudio JosÉ Struchiner
School of Applied Mathematics (EMAp FGV), Brazil
14 shared publications - M. Elizabeth Halloran
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA
14 shared publications M. Elizabeth Halloran
Center for Statistics and Quantitative Infectious Diseases, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109; and
8 shared publicationsLaura Matrajt
Department of Medicine, University of Washington, Seattle, WA, USA
6 shared publications- Dennis L. Chao
Institute for Disease Modeling; Bill & Melinda Gates Foundation
4 shared publications - Jonathan D. Sugimoto
International Vaccine Institute , Seoul
4 shared publications
Latest Publications
- Open Access
Critical immune and vaccination thresholds for determining multiple influenza epidemic waves
- 11 April 2011
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 108 (17) , 7081-7085
Vaccination strategies for epidemic cholera in Haiti with implications for the developing world
In October 2010, a virulent South Asian strain of El Tor cholera began to spread in Haiti. Interventions have included treatment of cases and improved sanitation. Use of cholera vaccines would likely have further reduced morbidity and mortality, but such vaccines are in short supply and little is known about effective vaccination strategies for epidemic cholera. We use a mathematical cholera transmission model to assess different vaccination strategies. With limited vaccine quantities, concentrating vaccine in high-risk areas is always most efficient. We show that targeting one million doses of vaccine to areas with high exposure to Vibrio cholerae , enough for two doses for 5% of the population, would reduce the number of cases by 11%. The same strategy with enough vaccine for 30% of the population with modest hygienic improvement could reduce cases by 55% and save 3,320 lives. For epidemic cholera, we recommend a large mobile stockpile of enough vaccine to cover 30% of a country's population to be reactively targeted to populations at high risk of exposure.
- 11 April 2011
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 108 (17) , 7081-7085
Vaccination strategies for epidemic cholera in Haiti with implications for the developing world
In October 2010, a virulent South Asian strain of El Tor cholera began to spread in Haiti. Interventions have included treatment of cases and improved sanitation. Use of cholera vaccines would likely have further reduced morbidity and mortality, but such vaccines are in short supply and little is known about effective vaccination strategies for epidemic cholera. We use a mathematical cholera transmission model to assess different vaccination strategies. With limited vaccine quantities, concentrating vaccine in high-risk areas is always most efficient. We show that targeting one million doses of vaccine to areas with high exposure to Vibrio cholerae , enough for two doses for 5% of the population, would reduce the number of cases by 11%. The same strategy with enough vaccine for 30% of the population with modest hygienic improvement could reduce cases by 55% and save 3,320 lives. For epidemic cholera, we recommend a large mobile stockpile of enough vaccine to cover 30% of a country's population to be reactively targeted to populations at high risk of exposure.
- Open Access
- 22 March 2011
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 173 (10) , 1121-1130
Planning for the Control of Pandemic Influenza A (H1N1) in Los Angeles County and the United States
Mathematical and computer models can provide guidance to public health officials by projecting the course of an epidemic and evaluating control measures. The authors built upon an existing collaboration between an academic research group and the Los Angeles County, California, Department of Public Health to plan for and respond to the first and subsequent years of pandemic influenza A (H1N1) circulation. The use of models allowed the authors to 1) project the timing and magnitude of the epidemic in Los Angeles County and the continental United States; 2) predict the effect of the influenza mass vaccination campaign that began in October 2009 on the spread of pandemic H1N1 in Los Angeles County and the continental United States; and 3) predict that a third wave of pandemic influenza in the winter or spring of 2010 was unlikely to occur. The close collaboration between modelers and public health officials during pandemic H1N1 spread in the fall of 2009 helped Los Angeles County officials develop a measured and appropriate response to the unfolding pandemic and establish reasonable goals for mitigation of pandemic H1N1.
- 22 March 2011
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 173 (10) , 1121-1130
Open AccessPlanning for the Control of Pandemic Influenza A (H1N1) in Los Angeles County and the United States
Mathematical and computer models can provide guidance to public health officials by projecting the course of an epidemic and evaluating control measures. The authors built upon an existing collaboration between an academic research group and the Los Angeles County, California, Department of Public Health to plan for and respond to the first and subsequent years of pandemic influenza A (H1N1) circulation. The use of models allowed the authors to 1) project the timing and magnitude of the epidemic in Los Angeles County and the continental United States; 2) predict the effect of the influenza mass vaccination campaign that began in October 2009 on the spread of pandemic H1N1 in Los Angeles County and the continental United States; and 3) predict that a third wave of pandemic influenza in the winter or spring of 2010 was unlikely to occur. The close collaboration between modelers and public health officials during pandemic H1N1 spread in the fall of 2009 helped Los Angeles County officials develop a measured and appropriate response to the unfolding pandemic and establish reasonable goals for mitigation of pandemic H1N1.
- 1 March 2011
- Published by Wolters Kluwer Health in Epidemiology
- Vol. 22 (2) , 180-187
The Effect of Age on Transmission of 2009 Pandemic Influenza A (H1N1) in a Camp and Associated Households
Background: A major portion of influenza disease burden during the 2009 pandemic was observed among young people. Methods: We examined the effect of age on the transmission of influenza-like illness associated with the 2009 pandemic influenza A (H1N1) virus (pH1N1) for an April–May 2009 outbreak among youth-camp participants and household contacts in Washington State. Results: An influenza-like illness attack rate of 51% was found among 96 camp participants. We observed a cabin secondary attack rate of 42% (95% confidence interval = 21%–66%) and a camp local reproductive number of 2.7 (1.7–4.1) for influenza-like illness among children (less than 18 years old). Among the 136 contacts in the 41 households with an influenza-like illness index case who attended the camp, the influenza-like illness secondary attack rate was 11% for children (5%–21%) and 4% for adults (2%–8%). The odds ratio for influenza-like illness among children versus adults was 3.1 (1.3–7.3). Conclusions: The strong age effect, combined with the low number of susceptible children per household (1.2), plausibly explains the lower-than-expected household secondary attack rate for influenza-like illness, illustrating the importance of other venues where children congregate for sustaining community transmission. Quantifying the effects of age on pH1N1 transmission is important for informing effective intervention strategies.
- 1 March 2011
- Published by Wolters Kluwer Health in Epidemiology
- Vol. 22 (2) , 180-187
The Effect of Age on Transmission of 2009 Pandemic Influenza A (H1N1) in a Camp and Associated Households
Background: A major portion of influenza disease burden during the 2009 pandemic was observed among young people. Methods: We examined the effect of age on the transmission of influenza-like illness associated with the 2009 pandemic influenza A (H1N1) virus (pH1N1) for an April–May 2009 outbreak among youth-camp participants and household contacts in Washington State. Results: An influenza-like illness attack rate of 51% was found among 96 camp participants. We observed a cabin secondary attack rate of 42% (95% confidence interval = 21%–66%) and a camp local reproductive number of 2.7 (1.7–4.1) for influenza-like illness among children (less than 18 years old). Among the 136 contacts in the 41 households with an influenza-like illness index case who attended the camp, the influenza-like illness secondary attack rate was 11% for children (5%–21%) and 4% for adults (2%–8%). The odds ratio for influenza-like illness among children versus adults was 3.1 (1.3–7.3). Conclusions: The strong age effect, combined with the low number of susceptible children per household (1.2), plausibly explains the lower-than-expected household secondary attack rate for influenza-like illness, illustrating the importance of other venues where children congregate for sustaining community transmission. Quantifying the effects of age on pH1N1 transmission is important for informing effective intervention strategies.
- Open Access
- 11 November 2010
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (11) , e13767
Optimizing Vaccine Allocation at Different Points in Time during an Epidemic
Pandemic influenza A(H1N1) 2009 began spreading around the globe in April of 2009 and vaccination started in October of 2009. In most countries, by the time vaccination started, the second wave of pandemic H1N1 2009 was already under way. With limited supplies of vaccine, we are left to question whether it may be a good strategy to vaccinate the high-transmission groups earlier in the epidemic, but it might be a better use of resources to protect instead the high-risk groups later in the epidemic. To answer this question, we develop a deterministic epidemic model with two age-groups (children and adults) and further subdivide each age group in low and high risk. We compare optimal vaccination strategies started at various points in time in two different settings: a population in a developed country where children account for 24% of the population, and a population in a less developed country where children make up the majority of the population, 55%. For each of these populations, we minimize mortality or hospitalizations and we find an optimal vaccination strategy that gives the best vaccine allocation given a starting vaccination time and vaccine coverage level. We find that population structure is an important factor in determining the optimal vaccine distribution. Moreover, the optimal policy is dynamic as there is a switch in the optimal vaccination strategy at some time point just before the peak of the epidemic. For instance, with 25% vaccine coverage, it is better to protect the high-transmission groups before this point, but it is optimal to protect the most vulnerable groups afterward. Choosing the optimal strategy before or early in the epidemic makes an important difference in minimizing the number of influenza infections, and consequently the number of influenza deaths or hospitalizations, but the optimal strategy makes little difference after the peak.
- 11 November 2010
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (11) , e13767
Open AccessOptimizing Vaccine Allocation at Different Points in Time during an Epidemic
Pandemic influenza A(H1N1) 2009 began spreading around the globe in April of 2009 and vaccination started in October of 2009. In most countries, by the time vaccination started, the second wave of pandemic H1N1 2009 was already under way. With limited supplies of vaccine, we are left to question whether it may be a good strategy to vaccinate the high-transmission groups earlier in the epidemic, but it might be a better use of resources to protect instead the high-risk groups later in the epidemic. To answer this question, we develop a deterministic epidemic model with two age-groups (children and adults) and further subdivide each age group in low and high risk. We compare optimal vaccination strategies started at various points in time in two different settings: a population in a developed country where children account for 24% of the population, and a population in a less developed country where children make up the majority of the population, 55%. For each of these populations, we minimize mortality or hospitalizations and we find an optimal vaccination strategy that gives the best vaccine allocation given a starting vaccination time and vaccine coverage level. We find that population structure is an important factor in determining the optimal vaccine distribution. Moreover, the optimal policy is dynamic as there is a switch in the optimal vaccination strategy at some time point just before the peak of the epidemic. For instance, with 25% vaccine coverage, it is better to protect the high-transmission groups before this point, but it is optimal to protect the most vulnerable groups afterward. Choosing the optimal strategy before or early in the epidemic makes an important difference in minimizing the number of influenza infections, and consequently the number of influenza deaths or hospitalizations, but the optimal strategy makes little difference after the peak.
- Top Cited Papers
- 30 October 2009
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 326 (5953) , 729-733
The Transmissibility and Control of Pandemic Influenza A (H1N1) Virus
Flu's Tricky Tricks: After vaccination against influenza A virus, single-point mutations are selected in hemagglutinin (the virus molecule that binds to sialic acid molecules on the surface of host cells) that escape neutralization by polyclonal antibody responses. Hensley et al. (p. 734 ) have discovered that in mice these mutations increased the virus's avidity for sialic acid. Amino acid substitutions that occur during reiterations of immune escape and avidity modulation can thus drive antigenic variation. This constant evolution of influenza viruses requires us to change vaccine components annually, and, for equine influenza, Park et al. (p. 726 ) show that as the match between virus and vaccine strains drifts apart with time, the probability of becoming infected and the length of the infectious period increase to the point where outbreaks occur. Nevertheless, even imperfect vaccines may be of benefit to a population because increasing the proportion of vaccinated individuals can supply enough herd immunity to offset a poor antigenic match, especially if used in conjunction with antiviral drugs. For humans, Yang et al. (p. 729 , published online 10 September) estimate that the rate of transmission within U.S. households puts influenza A 2009 H1N1 (the current pandemic “swine flu”) in the higher range of transmissibility, compared to past seasonal and pandemic strains. Thus, to achieve mitigation this fall, children should be the first recipients of vaccine, followed by adults—aiming overall for 70% coverage of the population.
- 30 October 2009
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 326 (5953) , 729-733
Top Cited PapersThe Transmissibility and Control of Pandemic Influenza A (H1N1) Virus
Flu's Tricky Tricks: After vaccination against influenza A virus, single-point mutations are selected in hemagglutinin (the virus molecule that binds to sialic acid molecules on the surface of host cells) that escape neutralization by polyclonal antibody responses. Hensley et al. (p. 734 ) have discovered that in mice these mutations increased the virus's avidity for sialic acid. Amino acid substitutions that occur during reiterations of immune escape and avidity modulation can thus drive antigenic variation. This constant evolution of influenza viruses requires us to change vaccine components annually, and, for equine influenza, Park et al. (p. 726 ) show that as the match between virus and vaccine strains drifts apart with time, the probability of becoming infected and the length of the infectious period increase to the point where outbreaks occur. Nevertheless, even imperfect vaccines may be of benefit to a population because increasing the proportion of vaccinated individuals can supply enough herd immunity to offset a poor antigenic match, especially if used in conjunction with antiviral drugs. For humans, Yang et al. (p. 729 , published online 10 September) estimate that the rate of transmission within U.S. households puts influenza A 2009 H1N1 (the current pandemic “swine flu”) in the higher range of transmissibility, compared to past seasonal and pandemic strains. Thus, to achieve mitigation this fall, children should be the first recipients of vaccine, followed by adults—aiming overall for 70% coverage of the population.
- 26 September 2009
- Published by Springer Nature
- p. 153-175
Further Evaluation of Protective Effects
- 26 September 2009
- Published by Springer Nature
- p. 103-129
Evaluating Protective Effects of Vaccination
Evaluating the direct protective effects of vaccines in the individuals who were vaccinated has been the focus of vaccine studies over the past century. Generally, interest has been in the ability of vaccination to prevent or to ameliorate disease rather than to prevent infection (Clements-Mann 1998). Ascertainment of cases is often done by finding suspected cases in the population under study in people who exhibit a set of symptoms. The suspected cases are then tested for biological confirmation of the infectious agent of interest. Alternatively, surveillance can ascertain cases reported in central registries. However they are ascertained, with most vaccines, clinical disease is the primary outcome of interest. When ascertainment is on clinical cases, most asymptomatic infections may go undetected. A different situation arises when infection is the primary outcome. To ascertain infections in asymptomatic people, an active follow-up method of testing asymptomatic people is needed. In this chapter we consider estimation and inference for direct protective effects of vaccination, VE S and VE SP , in studies that do not condition on exposure to infection.We consider aspects of the design of such studies. Several examples of randomized, double-blind (double-masked) controlled vaccine trials illustrate the standard approach to design and analysis of such studies. Our choice of studies to present was motivated largely because of their use as illustrations in other sections of the book. Most randomized and pivotal studies of vaccines have been based on VE SP or VE S . Much has been written on studies to meet the approval of the regulatory agencies, and the design of clinical trials generally. Our goal here is to consider how VE S and VE SP relate to other measures of vaccine effects within the dependent happening context, and consider a few design considerations. Because VE S and VE SP do not condition on exposure to infection, assumptions about the relative exposure opportunity in the vaccine and control groups are important.
- 26 September 2009
- Published by Springer Nature
- p. 103-129
Evaluating Protective Effects of Vaccination
Evaluating the direct protective effects of vaccines in the individuals who were vaccinated has been the focus of vaccine studies over the past century. Generally, interest has been in the ability of vaccination to prevent or to ameliorate disease rather than to prevent infection (Clements-Mann 1998). Ascertainment of cases is often done by finding suspected cases in the population under study in people who exhibit a set of symptoms. The suspected cases are then tested for biological confirmation of the infectious agent of interest. Alternatively, surveillance can ascertain cases reported in central registries. However they are ascertained, with most vaccines, clinical disease is the primary outcome of interest. When ascertainment is on clinical cases, most asymptomatic infections may go undetected. A different situation arises when infection is the primary outcome. To ascertain infections in asymptomatic people, an active follow-up method of testing asymptomatic people is needed. In this chapter we consider estimation and inference for direct protective effects of vaccination, VE S and VE SP , in studies that do not condition on exposure to infection.We consider aspects of the design of such studies. Several examples of randomized, double-blind (double-masked) controlled vaccine trials illustrate the standard approach to design and analysis of such studies. Our choice of studies to present was motivated largely because of their use as illustrations in other sections of the book. Most randomized and pivotal studies of vaccines have been based on VE SP or VE S . Much has been written on studies to meet the approval of the regulatory agencies, and the design of clinical trials generally. Our goal here is to consider how VE S and VE SP relate to other measures of vaccine effects within the dependent happening context, and consider a few design considerations. Because VE S and VE SP do not condition on exposure to infection, assumptions about the relative exposure opportunity in the vaccine and control groups are important.